Hot flashes — clinically called vasomotor symptoms — affect 75–80% of women during the menopause transition, with about 25% experiencing them as moderate to severe. They were treated as a mystery for decades. The mechanism is now well-characterized enough that drug development can target it specifically.
What's actually happening
Hot flashes originate in the hypothalamus — specifically in a group of neurons called KNDy (kisspeptin/neurokinin B/dynorphin). These neurons regulate the body's thermoneutral zone, the narrow temperature range your body considers normal. In reproductive years, estrogen suppresses KNDy activity. When estrogen falls during perimenopause and postmenopause, KNDy neurons hypertrophy and become hyperactive. The thermoneutral zone narrows dramatically — a tiny rise in core temperature that you wouldn't have noticed at age 35 now triggers a full sympathetic response: vasodilation, sweating, rapid heart rate.
First-line treatment: hormone therapy
Systemic estrogen — by patch, gel, spray, or oral tablet — reduces hot flash frequency by 75–90% in most women. NAMS, ACOG, and the Endocrine Society all designate HRT as first-line treatment for moderate-to-severe vasomotor symptoms when there are no contraindications. The "timing hypothesis" suggests benefits outweigh risks most strongly when started within 10 years of the FMP or before age 60.
Non-hormonal options
Fezolinetant (Veozah, FDA-approved 2023) is a neurokinin-3 receptor antagonist that directly modulates KNDy neuron activity — the first hot-flash drug designed for the mechanism. Reduces moderate-to-severe hot flashes by about 60%. SSRIs and SNRIs (paroxetine 7.5 mg is FDA-approved as Brisdelle; venlafaxine and escitalopram used off-label) reduce hot flashes 50–60%. Gabapentin (300–900 mg/day, often split with a bedtime dose) reduces them ~45% and is particularly useful for night sweats disrupting sleep. Oxybutynin reduces them ~60% but has anticholinergic side effects.
What has modest or weak evidence
Black cohosh, soy isoflavones, evening primrose oil, vitamin E, and acupuncture have all been studied. Effect sizes are typically small (5–25% reduction, often within the placebo range). Some women report meaningful improvement; the average effect across populations is modest. Cognitive behavioral therapy for hot flashes (CBT-HF) has the strongest evidence among behavioral approaches, with effects similar to gabapentin.
When hot flashes signal something else
See your clinician if hot flashes start before age 40 (premature ovarian insufficiency workup), if they're accompanied by unintended weight loss or fevers (rule out thyroid disease, infection, lymphoma), or if they began within weeks of starting a new medication (tamoxifen, aromatase inhibitors, opioids, and SSRIs paradoxically can cause vasomotor symptoms).
Informational only — discuss your specific situation with a clinician trained in menopause care.